Mireia Gausachs
Overview
Explore the profile of Mireia Gausachs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aliagas E, Alay A, Martinez-Iniesta M, Hernandez-Madrigal M, Cordero D, Gausachs M, et al.
Br J Cancer
. 2021 Sep;
125(10):1365-1376.
PMID: 34588615
Background: There is no effective therapy for patients with malignant pleural mesothelioma (MPM) who progressed to platinum-based chemotherapy and immunotherapy. Methods: We aimed to investigate the antitumor activity of CDK4/6...
2.
Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients
Vargas-Parra G, Del Valle J, Rofes P, Gausachs M, Stradella A, Moreno-Cabrera J, et al.
Hum Mutat
. 2020 Sep;
41(12):2128-2142.
PMID: 32906215
CHEK2 variants are associated with intermediate breast cancer risk, among other cancers. We aimed to comprehensively describe CHEK2 variants in a Spanish hereditary cancer (HC) cohort and adjust the American...
3.
Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, et al.
Clin Cancer Res
. 2017 Jun;
23(19):5936-5947.
PMID: 28645942
The majority of genomic alterations causing intratumoral heterogeneity (ITH) in colorectal cancer are thought to arise during early stages of carcinogenesis as a burst but only after truncal mutations in...
4.
Feliubadalo L, Tonda R, Gausachs M, Trotta J, Castellanos E, Lopez-Doriga A, et al.
Sci Rep
. 2017 Jan;
7:37984.
PMID: 28050010
Next generation sequencing panels have been developed for hereditary cancer, although there is some debate about their cost-effectiveness compared to exome sequencing. The performance of two panels is compared to...
5.
Azuara D, Ginesta M, Gausachs M, Rodriguez-Moranta F, Fabregat J, Busquets J, et al.
Clin Chem
. 2012 Jun;
58(9):1332-41.
PMID: 22745110
Background: Concomitant quantification of multiple mutant KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) alleles may provide information in addition to that provided by standard mutation-detection procedures. We assessed the...
6.
Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al.
Eur J Hum Genet
. 2012 Jan;
20(7):762-8.
PMID: 22274583
The analytical algorithm of Lynch syndrome (LS) is increasingly complex. BRAF V600E mutation and MLH1 promoter hypermethylation have been proposed as a screening tool for the identification of LS. The...
7.
Moncada-Pazos A, Obaya A, Fraga M, Viloria C, Capella G, Gausachs M, et al.
J Cell Sci
. 2009 Jul;
122(Pt 16):2906-13.
PMID: 19638407
Proteases have long been associated with tumor progression, given their ability to degrade extracellular matrix components and facilitate invasion and metastasis. However, recent findings indicate that different proteases can also...